Aratana Therapeutics Inc. to Report First Quarter Financial Results Conference Call and Webcast scheduled for May 13, 2014, 4:45 p.m. ET
KANSAS CITY, Kan., May 5, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:45 p.m. ET, to discuss its financial results for the quarter ended March 31, 2014.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
- 1 (877) 870-4263 (U.S./Canada)
- 1 (412) 317-0790 (international)
A replay of the call will be available for 90 days beginning at approximately 7:00 p.m. ET on May 13, 2014. Access numbers for this replay are:
- 1 (877) 344-7529 (U.S./Canada)
- 1 (412) 317-0088 (international)
- Conference ID: 10045693
An audio webcast will be also accessible via the Investors Relations section of the Aratana Therapeutics website aratana.investorroom.com. The webcast replay will also remain available for 90 days.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit http://www.aratana.com.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
email@example.com; (212) 375-2664
Andrew Mielach (media)
firstname.lastname@example.org; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.